SCHEMBL5137315

SCHEMBL5137315

CCOC(=O)CCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccc(C(=O)OC)cc1)Cc1ccc2c(c1)OCO2

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.51
TSHR P16473 2/20 0.42
SIRT2 Q8IXJ6 2/20 0.41
ALDH1A1 P00352 3/20 0.41
MAPT P10636 2/20 0.41
NPSR1 Q6W5P4 1/20 0.41
CFTR P13569 1/20 0.41
FAAH O00519 3/20 0.40
MGLL Q99685 1/20 0.40
DHODH Q02127 1/20 0.40
TP53 P04637 1/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
USP2 O75604 1/20 0.40
LMNA P02545 1/20 0.40
ALOX15 P16050 1/20 0.40
HSD17B10 Q99714 1/20 0.40
PPARG P37231 1/20 0.40
PPARA Q07869 1/20 0.40
GAA P10253 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4766751 0.93 C5AR1 (0.58) C5AR1TSHRSIRT2FAAHMGLL
SCHEMBL5136520 0.92 C5AR1 (0.61) C5AR1TSHRSIRT2ALDH1A1MAPT
SCHEMBL5134777 0.91 C5AR1 (0.53) C5AR1TSHRALDH1A1FAAHMGLL
SCHEMBL5136961 0.90 C5AR1 (0.53) C5AR1TSHRSIRT2ALDH1A1MAPT
SCHEMBL648086 0.88 C5AR1 (0.55) C5AR1TSHRSIRT2ALDH1A1MAPT
SCHEMBL5134492 0.86 GAA (0.44) ALDH1A1FAAHDHODHMEN1KMT2A
SCHEMBL5137399 0.86 GAA (0.43) TSHRSIRT2ALDH1A1MAPTFAAH
SCHEMBL651054 0.85 C5AR1 (0.52) C5AR1TSHRSIRT2ALDH1A1MAPT
SCHEMBL649777 0.84 C5AR1 (0.55) C5AR1TSHRSIRT2ALDH1A1MAPT
SCHEMBL5135637 0.84 C5AR1 (0.65) C5AR1TSHRSIRT2ALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed